查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1370961

非侵入性产前检测市场 - 2018-2028 年全球产业规模、份额、趋势、机会和预测，按产品类型、测试类型、方法、按应用、最终用户、地区和竞争细分

Non-invasive Prenatal Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Product Type, By Test Type, By Method, By Application, By End User, By Region and Competition
出版日期: | 出版商: TechSci Research | 英文 171 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2022年全球非侵入性产前检测（NIPT）市场估值达40.3亿美元，并预计在整个预测期内大幅成长，复合年增长率（CAGR）为7.38%，预计将达到61.6亿美元至2028 年。无创产前检测是一种革命性的产前筛检方法，需要分析孕妇的血液样本以识别潜在的胎儿异常。这项先进技术主要用于诊断唐氏症（21 三体症）、爱德华兹氏症候群（18 三体）、帕陶氏症候群（13 三体症）和特纳氏症等遗传性疾病，涉及检查母体血液中的DNA 片段。值得注意的是，该程序消除了绒毛膜绒毛取样（CVS）等侵入性过程的需要，提供了更安全的替代方案，并且可以在怀孕第九週后进行。

主要市场驱动因素

越来越重视早期发现与预防

市场概况
预测期 2024-2028
2022 年市场规模 40.3亿美元
2028 年市场规模 61.6亿美元
2023-2028 年复合年增长率 7.38%
成长最快的细分市场 微缺失症候群
最大的市场 北美洲

对早期检测和预防的日益关注极大地刺激了对非侵入性产前检测 (NIPT) 的需求。这种开创性的筛检技术能够透过简单的母体血液检测来识别发育中胎儿的特定遗传异常，这不同于羊膜穿刺术或绒毛膜绒毛取样（CVS）等传统的侵入性方法，这些方法具有流产的风险。 NIPT 是一种更安全的替代方案，可提供可靠的早期基因筛检。

先进筛选技术的可用性

基因组定序技术的进步，特别是次世代定序 (NGS)，简化了诊断流程，缩短了周转时间。这些进步促进了非侵入性诊断的发展，从而能够准确检测各种遗传性疾病。再加上基于 NGS 的 NIPT 测试的成长，增强了业界在保持竞争力的同时提供精确结果的能力。

医疗保健报销政策向基因覆盖的转变

报销政策的改变对于提高医疗服务的可负担性和可近性发挥关键作用。使 NIPT 对患者在经济上可行的调整可以提高采用率。与传统方法相比，NIPT 的非侵入性和准确性使其成为准父母的一个有吸引力的选择。当 NIPT 费用由保险承担时，它就成为更广泛的个人的可行选择。

遗传和先天性疾病的盛行率不断增加

遗传和先天性疾病盛行率的不断上升极大地增加了对 NIPT 的需求。随着意识的增强以及对家庭的影响变得显而易见，未来的父母​​会寻求各种方法来确保未出生孩子的福祉。 NIPT 作为一种非侵入性且准确的早期检测方法，已成为高风险族群的首选。

主要市场挑战

NIPT 的局限性

儘管 NIPT 准确度很高，但仍存在假阳性或假阴性结果的可能性。这种不确定性可能会让患者对完全依赖 NIPT 做出诊断决策犹豫不决。此外，NIPT 是一种筛检测试，需要后续侵入性诊断来确认阳性结果。

替代筛选和测试方法

传统的血清筛检测试、序贯筛检和羊膜穿刺术或 CVS 等侵入性方法由于熟悉度、建议或对准确性的看法可能仍然受到青睐。对 NIPT 益处的认识差距可能会使患者转向替代方案。

主要市场趋势

直接面向消费者测试的可用性

直接面向消费者 (DTC) NIPT 检测的可用性有可能大幅提升需求。 DTC 检测使个人无需医疗中介即可获得基因检测服务。儘管存在担忧，但 DTC 测试可以提高 NIPT 的认知度、可及性和利用率。

专注于植入前基因诊断

植入前遗传学诊断 (PGD) 和 NIPT 相结合，可在植入前和植入后提供全面的遗传健康评估。 NIPT 可以验证 PGD 结果并为父母提供有关遗传健康的保证。

细分市场洞察

产品类型见解

在产品类型细分市场中，三体性条件占主导地位，NIPT 成为检测21、18 和13 三体性的有效方法。该方法在体外受精(IVF) 怀孕中的卓越敏感性和特异性进一步增强了其重要性。

最终使用者见解

由于患者和医疗保健专业人员对 NIPT 的偏好不断增加，诊断实验室在最终用户类别中处于领先地位。检测量的激增和安全产前检测措施促进了该细分市场的成长。

区域洞察

到 2022 年，在基因检测、先进研究框架和报销支援需求的推动下，北美将占据最大的市场份额。欧洲紧随其后，因为唐氏症的盛行率很高，而且高龄产妇的生育率也很高。由于遗传因素怀孕人数激增和政府倡议，预计亚太地区将快速成长。

目录

第 1 章：产品概述

  • 市场定义
  • 市场范围
    • 涵盖的市场
    • 考虑学习的年份
    • 主要市场区隔

第 2 章：研究方法

  • 研究目的
  • 基线方法
  • 主要产业伙伴
  • 主要协会和二手资料来源
  • 预测方法
  • 数据三角测量与验证
  • 假设和限制

第 3 章：执行摘要

  • 市场概况
  • 主要市场细分概述
  • 主要市场参与者概述
  • 重点地区/国家概况
  • 市场驱动因素、挑战、趋势概述

第 4 章：客户之声

第 5 章：全球非侵入性产前检测 (NIPT) 市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依产品类型（消耗品、仪器）
    • 依测试类型（Materni 21、Harmony、Panaroma、Verifi、NIFTY、其他）
    • 依方法（超音波检测、生化筛检测试、无细胞 DNA 母体血浆检验、母体血液中的胎儿细胞检验、其他）
    • 按应用（三体、微缺失症候群、其他）
    • 按最终使用者（诊断实验室、医院、其他）
    • 按地区
    • 按公司划分 (2022)
  • 市场地图

第 6 章：北美非侵入性产前检测 (NIPT) 市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依产品类型
    • 按测试类型
    • 依方法
    • 按应用
    • 按最终用户
    • 按国家/地区
  • 北美：国家分析
    • 美国
    • 加拿大
    • 墨西哥

第 7 章：欧洲非侵入性产前检测 (NIPT) 市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依产品类型
    • 按测试类型
    • 依方法
    • 按应用
    • 按最终用户
    • 按国家/地区
  • 欧洲：国家分析
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙

第 8 章：亚太地区非侵入性产前检测 (NIPT) 市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依产品类型
    • 按测试类型
    • 依方法
    • 按应用
    • 按最终用户
    • 按国家/地区
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第 9 章：南美洲无创产前检测 (NIPT) 市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依产品类型
    • 按测试类型
    • 依方法
    • 按应用
    • 按最终用户
    • 按国家/地区
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 10 章：中东和非洲非侵入性产前检测 (NIPT) 市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依产品类型
    • 按测试类型
    • 依方法
    • 按应用
    • 按最终用户
    • 按国家/地区
  • MEA：国家分析
    • 南非无创产前检测 (NIPT)
    • 沙乌地阿拉伯无创产前检测 (NIPT)
    • 阿联酋无创产前检测 (NIPT)

第 11 章：市场动态

  • 司机
  • 挑战

第 12 章：市场趋势与发展

  • 近期发展
  • 併购
  • 产品发布

第 13 章：全球口腔临床营养市场：SWOT 分析

第 14 章：波特的五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 客户的力量
  • 替代产品的威胁

第15章：竞争格局

  • 商业概览
  • 服务内容
  • 最近的发展
  • 主要人员
  • SWOT分析
    • YOURGENE HEALTH Plc
    • Illumina, Inc.
    • Natera, Inc.
    • F.Hoffman La Roche Ltd.
    • Perkin Elmer Inc.
    • Laboratory Corporation of America Holdings
    • Eurofins LifeCodex GmbH
    • Progenity, Inc.
    • Genesis Genetics
    • Quest Diagnostics Incorporated

第 16 章：策略建议

第 17 章：关于我们与免责声明

简介目录
Product Code: 4669

The Global Non-Invasive Prenatal Testing (NIPT) Market achieved a valuation of USD 4.03 Billion in 2022 and is poised for substantial growth throughout the forecast period, exhibiting a Compound Annual Growth Rate (CAGR) of 7.38% and expected to reach USD 6.16 Billion through 2028. Non-Invasive Prenatal Testing is a revolutionary prenatal screening method that entails analyzing a pregnant woman's blood sample to identify potential fetal abnormalities. This advanced technique, primarily employed to diagnose genetic disorders like Down syndrome (trisomy 21), Edwards syndrome (trisomy 18), Patau syndrome (trisomy 13), and Turner syndrome, involves scrutinizing DNA fragments within the maternal blood. Remarkably, this procedure eliminates the need for invasive processes such as chorionic villus sampling (CVS), providing a safer alternative and can be administered after the ninth week of pregnancy.

Key Market Drivers

Increasing Emphasis on Early Detection and Prevention

Market Overview
Forecast Period2024-2028
Market Size 2022USD 4.03 Billion
Market Size 2028USD 6.16 Billion
CAGR 2023-20287.38%
Fastest Growing SegmentMicrodeletion Syndrome
Largest MarketNorth America

A rising focus on early detection and prevention has significantly fueled the demand for Non-Invasive Prenatal Testing (NIPT). This pioneering screening technique enables the identification of specific genetic abnormalities in a developing fetus through a straightforward maternal blood test, diverging from conventional invasive approaches like amniocentesis or chorionic villus sampling (CVS), which carry the risk of miscarriage. NIPT stands out as a safer alternative, offering reliable early genetic screening.

Availability of Advanced Screening Technologies

Advancements in genome sequencing technologies, particularly Next-Generation Sequencing (NGS), have streamlined diagnosis processes with reduced turnaround time. These advances facilitate the development of non-invasive diagnostics, enabling accurate detection of various genetic disorders. This, coupled with the growth of NGS-based NIPT tests, strengthens the industry's capability to provide precise results while maintaining competitiveness.

Healthcare Shift in Reimbursement Policies Towards Genetic Coverage

Alterations in reimbursement policies play a pivotal role in enhancing the affordability and accessibility of medical services. Adjustments that render NIPT financially feasible for patients can lead to heightened adoption rates. The non-invasive nature and accuracy of NIPT, as compared to traditional methods, position it as an appealing option for expectant parents. When NIPT costs are covered by insurance, it becomes a viable choice for a broader spectrum of individuals.

Increasing Prevalence of Genetic and Congenital Disorders

The escalating prevalence of genetic and congenital disorders significantly contributes to the demand for NIPT. As awareness grows and the impact on families becomes apparent, prospective parents seek means to ensure the well-being of their unborn children. NIPT, as a non-invasive and accurate method for early detection, emerges as a preferred choice for those at higher risk.

Key Market Challenges

Limitations of NIPT

Despite its high accuracy, there remains a possibility of false-positive or false-negative results in NIPT. This uncertainty might create hesitancy among patients in fully relying on NIPT for diagnostic decisions. Additionally, NIPT is a screening test, necessitating follow-up invasive diagnostics to confirm positive results.

Alternative Screening and Testing Methods

Traditional serum screening tests, sequential screening, and invasive methods like amniocentesis or CVS might still be favored due to familiarity, recommendations, or perceptions about accuracy. Awareness gaps about the benefits of NIPT might divert patients towards alternatives.

Key Market Trends

Availability of Direct-to-Consumer Tests

The availability of Direct-to-Consumer (DTC) NIPT tests holds the potential to substantially elevate demand. DTC testing empowers individuals to access genetic testing services without medical intermediaries. While concerns exist, DTC testing can augment awareness, accessibility, and utilization of NIPT.

Focus on Pre-Implantation Genetic Diagnosis

The combination of Pre-Implantation Genetic Diagnosis (PGD) and NIPT presents comprehensive genetic health assessment both pre- and post-implantation. NIPT can validate PGD results and provide assurance to parents regarding genetic health.

Segmental Insights

Product Type Insights

Within the product type segment, trisomy conditions dominate, and NIPT emerges as an effective method for detecting trisomy 21, 18, and 13. The method's exceptional sensitivity and specificity in pregnancies resulting from in-vitro fertilization (IVF) further bolster its significance.

End User Insights

Diagnostic laboratories lead the end-user category due to increased preference for NIPT among both patients and healthcare professionals. The surge in test volumes and initiatives for safe prenatal testing contribute to this segment's growth.

Regional Insights

In 2022, North America holds the largest market share, propelled by demand for genetic testing, advanced research framework, and reimbursement support. Europe follows due to high prevalence of Down syndrome and increased childbearing at advanced maternal ages. Asia Pacific is projected for rapid growth due to a surge in pregnancies with genetic conditions and governmental initiatives.

Key Market Players

  • YOURGENE HEALTH Plc
  • Illumina, Inc.
  • Natera, Inc.
  • F.Hoffman La Roche Ltd.
  • Perkin Elmer Inc.
  • Laboratory Corporation of America Holdings
  • Eurofins LifeCodex GmbH
  • Progenity, Inc.
  • Genesis Genetics
  • Quest Diagnostics Incorporated

Report Scope:

In this report, the Global Non-invasive Prenatal Testing (NIPT) Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below.

Non-invasive Prenatal Testing (NIPT) Market, By Product Type:

  • Consumables
  • Instruments

Non-invasive Prenatal Testing (NIPT) Market, By Test Type:

  • Materni 21
  • Harmony
  • Panaroma
  • Verifi
  • NIFTY
  • Others

Non-invasive Prenatal Testing (NIPT) Market, By Method:

  • Ultrasound Detection
  • Biochemical Screening Testing
  • Cell-Free DNA Maternal Plasma Tests
  • Fetal Cells in Maternal Blood Tests
  • Others

Non-invasive Prenatal Testing (NIPT) Market, By Application:

  • Trisomy
  • Microdeletion Syndrome
  • Others

Non-invasive Prenatal Testing (NIPT) Market, By End User:

  • Diagnostic Laboratories
  • Hospitals
  • Others

Non-invasive Prenatal Testing (NIPT) Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
  • Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Turkey
  • Egypt

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Non-invasive Prenatal Testing (NIPT) Market.

Available Customizations:

  • Global Non-invasive Prenatal Testing (NIPT) market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Non-invasive Prenatal Testing (NIPT) Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product Type (Consumables, Instruments)
    • 5.2.2. By Test Type (Materni 21, Harmony, Panaroma, Verifi, NIFTY, Others)
    • 5.2.3. By Method (Ultrasound Detection, Biochemical Screening Testing, Cell-Free DNA Maternal Plasma Tests, Fetal Cells in Maternal Blood Tests, Others)
    • 5.2.4. By Application (Trisomy, Microdeletion Syndrome, Others)
    • 5.2.5. By End User (Diagnostic Laboratories, Hospitals, Others)
    • 5.2.6. By Region
    • 5.2.7. By Company (2022)
  • 5.3. Market Map

6. North America Non-invasive Prenatal Testing (NIPT) Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
    • 6.2.2. By Test Type
    • 6.2.3. By Method
    • 6.2.4. By Application
    • 6.2.5. By End User
    • 6.2.6. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Non-invasive Prenatal Testing (NIPT) Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product Type
        • 6.3.1.2.2. By Test Type
        • 6.3.1.2.3. By Method
        • 6.3.1.2.4. By Application
        • 6.3.1.2.5. By End User
    • 6.3.2. Canada Non-invasive Prenatal Testing (NIPT) Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product Type
        • 6.3.2.2.2. By Test Type
        • 6.3.2.2.3. By Method
        • 6.3.2.2.4. By Application
        • 6.3.2.2.5. By End User
    • 6.3.3. Mexico Non-invasive Prenatal Testing (NIPT) Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product Type
        • 6.3.3.2.2. By Test Type
        • 6.3.3.2.3. By Method
        • 6.3.3.2.4. By Application
        • 6.3.3.2.5. By End User

7. Europe Non-invasive Prenatal Testing (NIPT) Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By Test Type
    • 7.2.3. By Method
    • 7.2.4. By Application
    • 7.2.5. By End User
    • 7.2.6. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Non-invasive Prenatal Testing (NIPT) Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product Type
        • 7.3.1.2.2. By Test Type
        • 7.3.1.2.3. By Method
        • 7.3.1.2.4. By Application
        • 7.3.1.2.5. By End User
    • 7.3.2. United Kingdom Non-invasive Prenatal Testing (NIPT) Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product Type
        • 7.3.2.2.2. By Test Type
        • 7.3.2.2.3. By Method
        • 7.3.2.2.4. By Application
        • 7.3.2.2.5. By End User
    • 7.3.3. Italy Non-invasive Prenatal Testing (NIPT) Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecasty
        • 7.3.3.2.1. By Product Type
        • 7.3.3.2.2. By Test Type
        • 7.3.3.2.3. By Method
        • 7.3.3.2.4. By Application
        • 7.3.3.2.5. By End User
    • 7.3.4. France Non-invasive Prenatal Testing (NIPT) Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product Type
        • 7.3.4.2.2. By Test Type
        • 7.3.4.2.3. By Method
        • 7.3.4.2.4. By Application
        • 7.3.4.2.5. By End User
    • 7.3.5. Spain Non-invasive Prenatal Testing (NIPT) Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product Type
        • 7.3.5.2.2. By Test Type
        • 7.3.5.2.3. By Method
        • 7.3.5.2.4. By Application
        • 7.3.5.2.5. By End User

8. Asia-Pacific Non-invasive Prenatal Testing (NIPT) Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By Test Type
    • 8.2.3. By Method
    • 8.2.4. By Application
    • 8.2.5. By End User
    • 8.2.6. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Non-invasive Prenatal Testing (NIPT) Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product Type
        • 8.3.1.2.2. By Test Type
        • 8.3.1.2.3. By Method
        • 8.3.1.2.4. By Application
        • 8.3.1.2.5. By End User
    • 8.3.2. India Non-invasive Prenatal Testing (NIPT) Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product Type
        • 8.3.2.2.2. By Test Type
        • 8.3.2.2.3. By Method
        • 8.3.2.2.4. By Application
        • 8.3.2.2.5. By End User
    • 8.3.3. Japan Non-invasive Prenatal Testing (NIPT) Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product Type
        • 8.3.3.2.2. By Test Type
        • 8.3.3.2.3. By Method
        • 8.3.3.2.4. By Application
        • 8.3.3.2.5. By End User
    • 8.3.4. South Korea Non-invasive Prenatal Testing (NIPT) Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product Type
        • 8.3.4.2.2. By Test Type
        • 8.3.4.2.3. By Method
        • 8.3.4.2.4. By Application
        • 8.3.4.2.5. By End User
    • 8.3.5. Australia Non-invasive Prenatal Testing (NIPT) Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product Type
        • 8.3.5.2.2. By Test Type
        • 8.3.5.2.3. By Method
        • 8.3.5.2.4. By Application
        • 8.3.5.2.5. By End User

9. South America Non-invasive Prenatal Testing (NIPT) Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By Test Type
    • 9.2.3. By Method
    • 9.2.4. By Application
    • 9.2.5. By End User
    • 9.2.6. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Non-invasive Prenatal Testing (NIPT) Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product Type
        • 9.3.1.2.2. By Test Type
        • 9.3.1.2.3. By Method
        • 9.3.1.2.4. By Application
        • 9.3.1.2.5. By End User
    • 9.3.2. Argentina Non-invasive Prenatal Testing (NIPT) Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product Type
        • 9.3.2.2.2. By Test Type
        • 9.3.2.2.3. By Method
        • 9.3.2.2.4. By Application
        • 9.3.2.2.5. By End User
    • 9.3.3. Colombia Non-invasive Prenatal Testing (NIPT) Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product Type
        • 9.3.3.2.2. By Test Type
        • 9.3.3.2.3. By Method
        • 9.3.3.2.4. By Application
        • 9.3.3.2.5. By End User

10. Middle East and Africa Non-invasive Prenatal Testing (NIPT) Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product Type
    • 10.2.2. By Test Type
    • 10.2.3. By Method
    • 10.2.4. By Application
    • 10.2.5. By End User
    • 10.2.6. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Non-invasive Prenatal Testing (NIPT) Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product Type
        • 10.3.1.2.2. By Test Type
        • 10.3.1.2.3. By Method
        • 10.3.1.2.4. By Application
        • 10.3.1.2.5. By End User
    • 10.3.2. Saudi Arabia Non-invasive Prenatal Testing (NIPT) Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product Type
        • 10.3.2.2.2. By Test Type
        • 10.3.2.2.3. By Method
        • 10.3.2.2.4. By Application
        • 10.3.2.2.5. By End User
    • 10.3.3. UAE Non-invasive Prenatal Testing (NIPT) Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product Type
        • 10.3.3.2.2. By Test Type
        • 10.3.3.2.3. By Method
        • 10.3.3.2.4. By Application
        • 10.3.3.2.5. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Global Oral Clinical Nutrition Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Service Offerings
  • 15.3. Recent Developments
  • 15.4. Key Personnel
  • 15.5. SWOT Analysis
    • 15.5.1. YOURGENE HEALTH Plc
    • 15.5.2. Illumina, Inc.
    • 15.5.3. Natera, Inc.
    • 15.5.4. F.Hoffman La Roche Ltd.
    • 15.5.5. Perkin Elmer Inc.
    • 15.5.6. Laboratory Corporation of America Holdings
    • 15.5.7. Eurofins LifeCodex GmbH
    • 15.5.8. Progenity, Inc.
    • 15.5.9. Genesis Genetics
    • 15.5.10. Quest Diagnostics Incorporated

16. Strategic Recommendations

17. About Us & Disclaimer